Desensitisation, also known as allergen immunotherapy, uniquely alters the natural course of respiratory allergies. Allergen immunotherapy is the only therapeutic class capable of modifying the disease progression and potentially preventing the onset of the disease by inducing tolerance in the immune system.
The current standard of care for respiratory allergies may be insufficient for disease control and the burden of disease is significant.
Allergen immunotherapy uniquely alters the natural course of respiratory allergies. Allergen immunotherapy is the only therapeutic class capable of modifying the disease progression and potentially preventing the onset of the disease by inducing tolerance in the immune system (source: Global Atlas of Allergy, EAACI 2014).
Allergen immunotherapy significantly reduces the symptoms of allergy and the use of symptomatic treatments. In addition, its effects are long lasting (source: Jacobsen L. et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007 Aug;62(8):943-8).
Allergen immunotherapy is a second line treatment intended for patients (from 5 years of age) with respiratory allergies and for whom symptomatic treatments are insufficient or not well tolerated.
AIT: a targeted treatment
Only an allergy specialist can prescribe an allergy immunotherapy treatment after an accurate diagnosis.
Allergen immunotherapy is a targeted treatment which consists in gradually administering to the patient repeated doses of allergenic extracts, which will reduce the hyper-reactivity of the immune system and the inflammation which results from it.
If the efficacy is observed after the first year of treatment, an AIT treatment can take between three to five years (source: Marogna M. et al., Long-lasting effects of sublingual immunotherapy according to its duration : A 15-year study. J Allergy Clin Immunology, 2010) to achieve long term efficacy.